# H. Miles Prince

Source: https://onco.cc/people/miles-prince/  
OnCo record `miles-prince` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Melbourne haematologist who led ALCANZA, the trial that showed brentuximab vedotin beats standard treatment for CD30-expressing cutaneous T-cell lymphoma.

## Summary

Miles Prince is a haematologist at the Peter MacCallum Cancer Centre and Epworth Healthcare in Melbourne. He was first author of the 2017 Lancet report of ALCANZA, the international phase 3 trial in which brentuximab vedotin produced more lasting responses than physician's choice of methotrexate or bexarotene in previously treated CD30-positive mycosis fungoides or primary cutaneous anaplastic large-cell lymphoma, leading to the drug's approval in this setting.

## Fields

- Kind: Person
- Last checked: 2026-09-18
- Tags: lymphoma; trialist
- Role: Haematologist, Peter MacCallum Cancer Centre and Epworth Healthcare, Melbourne
- Specialisms: Cutaneous T-cell lymphoma; Multiple myeloma; Novel agents in lymphoma

## Connected records

- cancers: [Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome)](https://onco.cc/cancers/cutaneous-t-cell-lymphoma/), [Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma)](https://onco.cc/cancers/peripheral-t-cell-lymphoma/)
- institutions: [Peter MacCallum Cancer Centre](https://onco.cc/institutions/peter-mac/)
- trials: [ALCANZA](https://onco.cc/trials/alcanza/)
- key papers: [ALCANZA: brentuximab vedotin versus physician's choice in CD30-positive cutaneous T-cell lymphoma](https://onco.cc/key-papers/paper-alcanza-brentuximab-vedotin-lancet-2017/)

---
JSON: https://onco.cc/api/v1/entities/miles-prince.json